You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Details for New Drug Application (NDA): 217415


✉ Email this page to a colleague

« Back to Dashboard


NDA 217415 describes DAPTOMYCIN, which is a drug marketed by Accord Hlthcare, Aspiro, Be Pharms, Biocon Pharma, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Hainan Poly Pharm, Hangzhou Zhongmei, Hengrui Pharma, Hisun Pharm Hangzhou, Hospira, Meitheal, Mylan, Mylan Labs Ltd, Qilu Pharm Hainan, Sagent Pharms Inc, Teva Pharms Usa, Xellia Pharms Aps, and Baxter Hlthcare Corp, and is included in thirty NDAs. It is available from twenty-six suppliers. There are four patents protecting this drug. Additional details are available on the DAPTOMYCIN profile page.

The generic ingredient in DAPTOMYCIN is daptomycin. There are ten drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the daptomycin profile page.
Summary for 217415
Tradename:DAPTOMYCIN
Applicant:Xellia Pharms Aps
Ingredient:daptomycin
Patents:2
Pharmacology for NDA: 217415
Medical Subject Heading (MeSH) Categories for 217415
Suppliers and Packaging for NDA: 217415
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DAPTOMYCIN daptomycin POWDER;INTRAVENOUS 217415 NDA Xellia Pharmaceuticals USA LLC 70594-060 70594-060-01 1 VIAL, SINGLE-USE in 1 CARTON (70594-060-01) / 10 mL in 1 VIAL, SINGLE-USE
DAPTOMYCIN daptomycin POWDER;INTRAVENOUS 217415 NDA Xellia Pharmaceuticals USA LLC 70594-066 70594-066-01 1 VIAL, SINGLE-USE in 1 CARTON (70594-066-01) / 7 mL in 1 VIAL, SINGLE-USE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;INTRAVENOUSStrength350MG/VIAL
Approval Date:Jan 30, 2023TE:RLD:Yes
Patent:⤷  Sign UpPatent Expiration:Aug 28, 2038Product Flag?YSubstance Flag?Delist Request?
Patent:⤷  Sign UpPatent Expiration:Aug 28, 2038Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOOD STREAM INFECTIONS

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:POWDER;INTRAVENOUSStrength500MG/VIAL
Approval Date:Jan 30, 2023TE:RLD:Yes
Patent:⤷  Sign UpPatent Expiration:Aug 28, 2038Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.